Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published in The New…
CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced publication in The New England Journal of Medicine (NEJM) of the results from…